Copyright
©The Author(s) 2020.
World J Gastroenterol. Jun 7, 2020; 26(21): 2792-2809
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2792
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2792
Table 5 Analysis of the percentage reduction of the mean relative tumor area in the treated subgroups in comparison to the control group
| Threshold value | Number of cases, n (%) | |||
| k vs FOLFOXIRI | k vs GEMOX | k vs Gem/nab-P | k vs Gemcitabine | |
| -10% | 13 (87) | 13 (87) | 12 (80) | 13 (87) |
| -20% | 12 (80) | 10 (67) | 11 (73) | 11 (73) |
| -30% | 11 (73) | 8 (53) | 9 (60) | 8 (53) |
| -40% | 10 (67) | 6 (40) | 7 (47) | 7 (47) |
| -50% | 7 (47) | 5 (33) | 4 (27) | 4 (27) |
| -60% | 5 (33) | 1 (7) | 4 (27) | 1 (7) |
| -70% | 1 (7) | 1 (7) | 1 (7) | 0 (0) |
| -80% | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
- Citation: Di Franco G, Usai A, Funel N, Palmeri M, Montesanti IER, Bianchini M, Gianardi D, Furbetta N, Guadagni S, Vasile E, Falcone A, Pollina LE, Raffa V, Morelli L. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World J Gastroenterol 2020; 26(21): 2792-2809
- URL: https://www.wjgnet.com/1007-9327/full/v26/i21/2792.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i21.2792